• 2415 Citations
  • 27 h-Index
1967 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

A new approach involving drug delivery to cancerous breast tumors is proposed. The method involves the encapsulation of an anti-cancer agent (such as taxol [pacliataxel]) into artificial cholesterol complexes as novel delivery vehicles. These complexes resemble high density lipoproteins (good cholesterol carriers, HDL) and they markedly improve the solubility and transportability of otherwise poorly soluble drugs. The proposed studies include: Testing of the HDL/drug complexes against several breast tumor cells, by comparing their killing potential to that of the free drug and testing the efficacy of the HDL/drug preparation against breast tumors carried by mice (in vivo). Future studies would include clinical trials with appropriate formulations.
If successful, these studies will establish a new generation of chemotherapeutic agents against breast cancer and thus substantially enhance the quality of life and the survival of patients. Furthermore, the proposed formulation may provide an improved treatment modality for breast cancer as the encapsulated drug preparation is expected to have reduced toxicity against normal cells and tissues (particularly heart tissue). This approach has the potential to markedly improve the delivery of anticancer drugs to target tissues and thus improve the chemotherapy and may even provide a cure for breast cancer.

Education/Academic qualification

PhD in Biochemistry, University of Washington

Award Date: 1 Jan 2002

MS in Microbiology, University of British Columbia

Award Date: 1 Jan 2001

BS in Food Technology, University of British Columbia

Award Date: 1 Jan 2000

Fingerprint Dive into the research topics where Andras Lacko is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

[ 99 mTc-HYNIC-N-dodecylamide]:a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging

Isaac-Olivé, K., Ocampo-García, B. E., Aranda-Lara, L., Santos-Cuevas, C. L., Jiménez-Mancilla, N. P., Luna-Gutiérrez, M. A., Medina, L. A., Nagarajan, B., Sabnis, N., Raut, S., Prokai, L. & Lacko, A. G., 14 Jan 2019, In : Nanoscale. 11, 2, p. 541-551 11 p.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    Identifying and targeting angiogenesis-related microRNAs in ovarian cancer

    Chen, X., Mangala, L. S., Mooberry, L., Bayraktar, E., Dasari, S. K., Ma, S., Ivan, C., Court, K. A., Rodriguez-Aguayo, C., Bayraktar, R., Raut, S., Sabnis, N., Kong, X., Yang, X., Lopez-Berestein, G., Lacko, A. G. & Sood, A. K., 15 Aug 2019, In : Oncogene. 38, 33, p. 6095-6108 14 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    The SR-B1 Receptor as a Potential Target for Treating Glioblastoma

    Berney, E., Sabnis, N., Panchoo, M., Raut, S., Dickerman, R. & Lacko, A. G., 1 Jan 2019, In : Journal of Oncology. 2019, 1805841.

    Research output: Contribution to journalArticle

    Open Access
  • 2 Scopus citations

    Lipoproteins for therapeutic delivery: Recent advances and future opportunities

    Raut, S., Dasseux, J. L., Sabnis, N. A., Mooberry, L. & Lacko, A., 1 Jan 2018, In : Therapeutic Delivery. 9, 4, p. 257-268 12 p.

    Research output: Contribution to journalReview article

  • 7 Scopus citations

    Reconstituted HDL: Drug delivery platform for overcoming biological barriers to cancer therapy

    Raut, S., Mooberry, L., Sabnis, N., Garud, A., Dossou, A. S. & Lacko, A., 15 Oct 2018, In : Frontiers in Pharmacology. 9, OCT, 01154.

    Research output: Contribution to journalReview article

  • 4 Scopus citations